Teva Pharmaceuticals and the Parkinson's Unity Walk on Friday announced the launch of a public awareness campaign, "CommUNITY: Carrying the PD Torch," to support Parkinson's disease patients during Parkinson's Disease Awareness Month in April.
Healthcare Distribution Management Association president and CEO John Gray on Monday testified before the House Energy and Commerce Subcommittee on Health at a hearing on “Improving Predictability and Transparency in DEA and FDA Regulation.”
Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.
Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.
Medication nonadherence is common, but it may be reduced by lower drug costs and co-payments, as well as increased follow-up care, according to a study published earlier this week in the Annals of Internal Medicine.
IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders.